剂泰医药 METiS specializes in AI-driven drug delivery and drug discovery, self-described.

剂泰医药 METiS

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Alkermes Inc. plc

Metis Biotechnology specializes in air dynamics and air filtration technology, providing solutions for cleanroom and biosafety needs. The company develops and manufactures molecular diagnostic tests and biodegradable high-performance products.

Metric
Company Name	剂泰医药 METiS	Alkermes Inc. plc	Metis Biotechnology
Symbol		ALKS
MSH ID	COM:METISPHARMA	COM:ALKERMES	COM:METISBIO
Market	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Technology
Industry	Pharmaceuticals	Biotechnology	Biotechnology
Country	CN	US	TR
Stage
Employee Count		2.10K
Website	metispharma.com	alkermes.com	metisbio.com
LinkedIn
Founders

Metric
Market Cap		4.87B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		1.66B
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.37B
EBITDA		486.73M
Operating Income		414.12M
Net Income		355.76M
EPS		2.14
Diluted EPS		2.10
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.87
Operating Profit Margin		0.22
EBITDA Margin		0.29
Net Profit Margin		0.25
Return on Equity		0.34
Return on Assets		0.20
Return on Capital Employed		0.23

COM:METISPHARMA

剂泰医药 METiS

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		20.48
P/B Ratio		3.24
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.17
EV Multiple		16.57

Metric
Days Sales Outstanding		78.13
Days Payables Outstanding		94.07
Days Inventory Outstanding		352.33
Operating Cycle		441.02
Cash Conversion Cycle		441.02
Asset Turnover		0.81

Metric
Operating Cash Flow		401.35M
Free Cash Flow		353.31M
Cash Flow to Debt		1.50
Operating Cash Flow/Sales		0.29
Free Cash Flow Yield		0.06

Metric
Cash & Equivalents		457.47M
Accounts Receivable		-44.51M
Inventory		186.41M
Goodwill		83.03M
Debt to Capitalization		0.22
Debt to Assets		0.13
Current Ratio		3.12
Quick Ratio		2.77

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.06
R&D to Revenue		0.19
SG&A to Revenue		0.17